# colorectal cancer - minimax-m3

- Benchmark system: raw
- Repeat: 4
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 3761
- Completion tokens: 9916
- Reasoning tokens: 
- Total tokens: 13677
- API requests reported: 
- Elapsed seconds: 50.9
- Final benchmark system: raw; file rank 3/5; original repeat 4; model vendor: MiniMax

---
<think>The user wants me to perform a comprehensive prognostic transcriptomics interpretation for colorectal cancer (CRC) based on a gene list with hazard ratios (HR), P values, and FDR. This is a prognostic analysis (OS endpoint), not a differential expression analysis. Let me carefully analyze the data and provide an evidence-based interpretation.

Let me first organize the data:

**Risk-associated genes (HR > 1, poor prognosis):**
- INHBB (HR=1.43, FDR=0.0011) - Inhibin beta B, TGF-β superfamily
- SCARA3 (HR=1.38, FDR=0.0024) - Scavenger receptor class A
- MIR31HG (HR=1.31, FDR=0.0066) - lncRNA
- ZEB1-AS1 (HR=1.37, FDR=0.0086) - lncRNA antisense to ZEB1
- DCBLD2 (HR=1.41, FDR=0.0086) - Discoidin, CUB and LCCL domain containing 2
- TPM4 (HR=1.36, FDR=0.0089) - Tropomyosin 4
- NPR3 (HR=1.35, FDR=0.0164) - Natriuretic peptide receptor 3
- LRRC8A (HR=1.38, FDR=0.0250)
- PTPN14 (HR=1.36, FDR=0.0250) - Protein tyrosine phosphatase
- ITGBL1 (HR=1.30, FDR=0.0306) - Integrin beta-like 1
- ABL2 (HR=1.30, FDR=0.0276)
- NIN (HR=1.35, FDR=0.0282)
- AKT3 (HR=1.32, FDR=0.0388) - Akt kinase family
- NT5E (HR=1.31, FDR=0.0394) - CD73, ecto-5'-nucleotidase
- MSLN (HR=1.31, FDR=0.0451) - Mesothelin
- FGF19 (HR=1.29, FDR=0.0512) - Fibroblast growth factor 19
- BACE1 (HR=1.33, FDR=0.0466)
- SLC2A3 (HR=1.28, FDR=0.0722) - GLUT3
- MAP1B (HR=1.33, FDR=0.0472)
- GADD45B (HR=1.32, FDR=0.0630)
- CYP1B1 (HR=1.29, FDR=0.0630)
- Various PROBEs (likely unannotated or probe-level features)

**Protective genes (HR < 1, better prognosis):**
- ATP23 (HR=0.69, FDR=0.0066) - ATP23 metallopeptidase
- NDUFA9 (HR=0.69, FDR=0.0086) - NADH:ubiquinone oxidoreductase
- SLC35G1 (HR=0.69, FDR=0.0164)
- SH3RF2 (HR=0.73, FDR=0.0192)
- TAPBPL (HR=0.71, FDR=0.0192)
- MYB (HR=0.77, FDR=0.0192) - Transcription factor
- GLYCTK (HR=0.71, FDR=0.0203)
- CCDC134 (HR=0.71, FDR=0.0252)
- PPFIBP2 (HR=0.76, FDR=0.0261)
- PXMP2 (HR=0.72, FDR=0.0276)
- MCCC2 (HR=0.74, FDR=0.0282)
- MYO5B (HR=0.75, FDR=0.0282)
- RAB11FIP4 (HR=0.74, FDR=0.0329)
- ILVBL (HR=0.72, FDR=0.0329)
- OGFOD2 (HR=0.72, FDR=0.0355)
- KIAA1671 (HR=0.74, FDR=0.0355)
- ASL (HR=0.74, FDR=0.0355)
- CDX2 (HR=0.75, FDR=0.0359) - Caudal type homeobox 2
- DNPEP (HR=0.73, FDR=0.0361)
- CS (HR=0.75, FDR=0.0388) - Citrate synthase
- TIMM13 (HR=0.75, FDR=0.0394)
- JAGN1 (HR=0.74, FDR=0.0394)
- PRELID2 (HR=0.76, FDR=0.0404)
- LGALS9 (HR=0.75, FDR=0.0420)
- COA3 (HR=0.74, FDR=0.0434)
- RNF34 (HR=0.74, FDR=0.0436)
- CASP6 (HR=0.77, FDR=0.0453)
- BCL2L14 (HR=0.76, FDR=0.0394)
- LGALS4 (HR=0.77, FDR=0.0512)
- CRYM (HR=0.73, FDR=0.0510)
- ATP5G1 (HR=0.75, FDR=0.0519)
- CDX1 (HR=0.78, FDR=0.0573)
- USP3 (HR=0.76, FDR=0.0579)
- ATP5B (HR=0.75, FDR=0.0593)
- NSMCE4A (HR=0.74, FDR=0.0597)
- ACSS2 (HR=0.76, FDR=0.0602)
- CNOT1 (HR=0.76, FDR=0.0603)
- METTL7B (HR=0.76, FDR=0.0678)
- AQP11 (HR=0.74, FDR=0.0678)
- GMNN (HR=0.76, FDR=0.0678) - Geminin, DNA replication inhibitor
- ZBED3 (HR=0.76, FDR=0.0685)
- OGDHL (HR=0.69, FDR=0.0744) - Oxoglutarate dehydrogenase L
- ZNF667 (HR=1.29, FDR=0.0761) - this is actually HR > 1, risk
- DBI (HR=0.77, FDR=0.0573)

Now let me identify the major biological themes:

1. **Intestinal differentiation / epithelial identity**: CDX2 and CDX1 (protective) - these are master regulators of intestinal differentiation. Loss of CDX2 is associated with poor prognosis in CRC. This is a strong theme.

2. **TGF-β superfamily / growth factor signaling**: INHBB (risk), FGF19 (risk) - both associated with poorer outcomes. INHBB is a TGF-β family member, and FGF19 is an enterokine associated with CRC.

3. **EMT and mesenchymal phenotype**: ZEB1-AS1 (risk, lncRNA that regulates ZEB1), TPM4 (risk), ITGBL1 (risk), SCEL (risk) - these point toward EMT. ZEB1-AS1 is well-known to regulate ZEB1 and promote EMT.

4. **Energy metabolism / mitochondrial function**: Many protective genes are mitochondrial (NDUFA9, ATP5G1, ATP5B, OGDHL, CS, TIMM13, COA3, ACSS2). This suggests intact mitochondrial function is protective. NDUFA9 is Complex I, ATP5G1/B are ATP synthase, CS is citrate synthase (TCA cycle), OGDHL is part of α-KG dehydrogenase complex, ACSS2 is acetyl-CoA synthetase.

5. **Cell adhesion and ECM**: ITGBL1 (risk), PPFIBP2 (protective), MSLN (risk), BACE1 (risk) - mix of adhesion/ECM components.

6. **Wnt/β-catenin pathway**: MYB (protective, though MYB has complex roles), ZBED3 (protective - actually ZBED3 is a Wnt signaling component that enhances β-catenin signaling in some contexts). This is mixed.

7. **Akt/PI3K signaling**: AKT3 (risk) - oncogenic signaling

8. **Immune modulation**: NT5E (CD73, risk) - adenosine production, immunosuppressive. LGALS9 (protective) - galectin-9, can be immunosuppressive or activate immune response.

9. **Replication/cell cycle**: GMNN (protective, but geminin inhibits replication), GADD45B (risk - stress response).

Let me think about this more carefully and prioritize the most prominent themes.

Looking at the strongest signals:
- INHBB (HR=1.43, top risk)
- DCBLD2 (HR=1.41, top risk)
- SCARA3 (HR=1.38)
- ZEB1-AS1 (HR=1.37) - EMT regulator
- PTPN14 (HR=1.36) - phosphatase, YAP regulator
- TPM4 (HR=1.36) - cytoskeleton/EMT
- NPR3 (HR=1.35) - signaling
- NIN (HR=1.35) - centrosome
- MAP1B (HR=1.33) - microtubule associated
- BACE1 (HR=1.33)
- AKT3 (HR=1.32) - pro-survival signaling
- NT5E (HR=1.31) - CD73, immunosuppression
- MSLN (HR=1.31) - mesothelin
- MIR31HG (HR=1.31) - lncRNA
- FGF19 (HR=1.29) - growth factor

For protective:
- OGDHL (HR=0.69) - mitochondrial
- ATP23 (HR=0.69)
- NDUFA9 (HR=0.69) - Complex I
- SLC35G1 (HR=0.69)
- GLYCTK (HR=0.71)
- TAPBPL (HR=0.71)
- CCDC134 (HR=0.71)
- PXMP2 (HR=0.72)
- DNPEP (HR=0.73)
- ILVBL (HR=0.72)
- OGFOD2 (HR=0.72)
- CRYM (HR=0.73)
- SH3RF2 (HR=0.73)
- MCCC2 (HR=0.74)
- JAGN1 (HR=0.74)
- NSMCE4A (HR=0.74)
- COA3 (HR=0.74)
- ASL (HR=0.74)
- RAB11FIP4 (HR=0.74)
- AQP11 (HR=0.74)
- RNF34 (HR=0.74)
- KIAA1671 (HR=0.74)
- CDX2 (HR=0.75) - differentiation
- CS (HR=0.75) - TCA cycle
- TIMM13 (HR=0.75)
- ATP5G1 (HR=0.75) - ATP synthase
- LGALS9 (HR=0.75)
- ATP5B (HR=0.75) - ATP synthase
- BCL2L14 (HR=0.76)
- PPFIBP2 (HR=0.76)
- MYO5B (HR=0.75)
- USP3 (HR=0.76)
- PRELID2 (HR=0.76)
- METTL7B (HR=0.76)
- ZBED3 (HR=0.76)
- GMNN (HR=0.76)
- ACSS2 (HR=0.76)
- CNOT1 (HR=0.76)
- LGALS4 (HR=0.77) - galectin-4, intestinal
- CASP6 (HR=0.77)
- DBI (HR=0.77)
- MYB (HR=0.77)
- CDX1 (HR=0.78)
- PRR15L (HR=0.80)

Major themes:

**Theme 1: EMT and mesenchymal/invasive phenotype (Risk)**
- ZEB1-AS1 (risk) - antisense lncRNA, regulates ZEB1
- TPM4 (risk) - tropomyosin, cytoskeletal
- ITGBL1 (risk) - integrin-like, promotes EMT/TGF-β
- DCBLD2 (risk) - involved in cell migration
- MAP1B (risk) - microtubule-associated
- SCEL (risk)
- PTPN14 (risk) - regulates YAP, can be lost in cancers

**Theme 2: Intestinal epithelial differentiation (Protective)**
- CDX2 (HR=0.75) - master intestinal transcription factor
- CDX1 (HR=0.78) - intestinal TF
- LGALS4 (HR=0.77) - galectin-4, intestinal epithelial marker
- MYO5B (HR=0.75) - brush border myosin

**Theme 3: Mitochondrial metabolism / oxidative phosphorylation (Protective)**
- NDUFA9 (HR=0.69) - Complex I subunit
- ATP5G1 (HR=0.75) - ATP synthase F0 subunit
- ATP5B (HR=0.75) - ATP synthase F1 subunit
- OGDHL (HR=0.69) - α-ketoglutarate dehydrogenase
- CS (HR=0.75) - citrate synthase
- ACSS2 (HR=0.76) - acetyl-CoA synthetase
- TIMM13 (HR=0.75) - mitochondrial import
- COA3 (HR=0.74) - cytochrome c oxidase assembly
- PXMP2 (HR=0.72) - peroxisomal (also metabolic)

**Theme 4: TGF-β superfamily and growth factor signaling (Risk)**
- INHBB (HR=1.43) - Inhibin βB, TGF-β family
- FGF19 (HR=1.29) - FGF family
- AKT3 (HR=1.32) - Akt signaling
- PTPN14 (HR=1.36) - tyrosine phosphatase

**Theme 5: Immune microenvironment**
- NT5E (CD73, risk) - adenosine production, immunosuppressive
- LGALS9 (HR=0.75, protective) - galectin-9, complex role
- CCL15-CCL14/CCL15 (HR=0.75, protective) - chemokines
- BCL2L14 (HR=0.76, protective) - pro-apoptotic

Let me also note other relevant themes:
- Cell cycle: GADD45B (risk, stress/DNA damage response)
- Wnt signaling: ZBED3 (protective, can be Wnt positive regulator), MYB (protective, complex)

I should also think about which genes are most biologically meaningful and have the strongest statistical evidence.

Now I need to think about the core biological programs. Let me prioritize 5:

1. **EMT / mesenchymal invasive phenotype** (risk) - supported by ZEB1-AS1, TPM4, ITGBL1, MAP1B, DCBLD2, SCEL, PTPN14
2. **Intestinal differentiation / epithelial identity** (protective) - CDX2, CDX1, LGALS4, MYO5B
3. **Mitochondrial metabolism / oxidative phosphorylation** (protective) - NDUFA9, ATP5G1, ATP5B, OGDHL, CS, ACSS2, TIMM13, COA3
4. **TGF-β / growth factor signaling** (risk) - INHBB, FGF19, AKT3
5. **Immune microenvironment / adenosine signaling** (risk via NT5E) - NT5E, LGALS9

Or alternatively, I could pick:
5. Cell cycle / DNA damage response - GADD45B (risk), GMNN (protective)

Let me finalize my analysis. Let me consider the most coherent biological programs.

Key genes for detailed analysis:
1. INHBB - highest HR, TGF-β family
2. DCBLD2 - high HR, neuropilins, EMT
3. ZEB1-AS1 - EMT lncRNA
4. CDX2 - master intestinal TF, protective
5. NT5E (CD73) - immune suppression
6. AKT3 - survival signaling
7. MSLN - mesothelin, marker
8. FGF19 - growth factor
9. NDUFA9 - Complex I, mitochondrial
10. SCARA3 - scavenger receptor

Let me draft the response now.

I should structure my response clearly:
1. Overall biological interpretation
2. Core biological programs (≤5)
3. Key genes and interaction modules (≤10)
4. Validation priorities (≤5)
5. Evidence grounding (integrated throughout)
6. Limitations and alternative explanations (≤5)

Let me write this up properly.

For validation priorities:
1. CDX2/CDX1 intestinal differentiation - biomarker
2. NT5E (CD73) - therapeutic target (adenosine pathway inhibitors exist)
3. ZEB1-AS1 / EMT signature - mechanistic/biomarker
4. Mitochondrial / OXPHOS signature - mechanistic
5. INHBB / TGF-β - mechanistic

Limitations:
1. Cox model confounders (stage, MSI, etc.)
2. Probe-level features (PROBEs) - not annotated
3. Tissue heterogeneity / tumor purity
4. Multiple testing burden despite FDR
5. Cross-platform comparability

Let me also think about the evidence quality. The data appears to be from a microarray-based prognostic study (note PROBE_ entries suggest Affymetrix probe IDs).

Let me write the response in a comprehensive but focused manner.

One more thought - the gene list has both annotated genes and probe-level features (PROBE_xxx_at). I should note that the probe features are uncharacterized and shouldn't be over-interpreted.

Let me also double-check a few key genes:

- ZEB1-AS1: Known lncRNA that regulates ZEB1 expression, promotes EMT. Risk factor in CRC makes biological sense.
- ITGBL1: Integrin β-like 1, promotes EMT via TGF-β signaling in CRC. Risk factor consistent.
- DCBLD2: Neuropilin-like, can act as a receptor. Some studies show it's overexpressed in aggressive cancers.
- PTPN14: Tyrosine phosphatase, can regulate YAP, often lost in cancers (tumor suppressor in some contexts). Risk association here is interesting.
- SCARA3: Scavenger receptor, unclear in CRC.
- INHBB: Inhibin βB. Forms Activin B. Activin signaling has been linked to CRC progression.
- NT5E/CD73: Generates adenosine, immunosuppressive, known poor prognostic factor in CRC.
- MSLN: Mesothelin, overexpressed in some CRCs, associated with poor prognosis.
- FGF19: Enterokine, can drive proliferation, FGF19-FGFR4 axis is oncogenic.
- AKT3: Akt family kinase, pro-survival.

Protective:
- CDX2: Master intestinal TF, loss associated with poor prognosis in CRC. Strong evidence.
- CDX1: Similar role, less well characterized but related.
- NDUFA9: Complex I subunit. Lower expression associated with worse outcome - consistent with Warburg reversal or mitochondrial dysfunction being detrimental.
- ATP5B/ATP5G1: ATP synthase subunits.
- OGDHL: Similar to OGDH, part of α-KG dehydrogenase.
- LGALS4: Galectin-4, intestinal epithelial marker.
- MYO5B: Brush border myosin, intestinal.

OK, I think I have a good understanding. Let me write the final response.

Actually, one consideration - some of these genes are part of normal intestinal differentiation/function. If the tumor has lost differentiated features (dedifferentiated/stem-like), it tends to be more aggressive. So protective genes being "intestinal differentiation" genes is consistent with the well-known idea that differentiated CRC has better prognosis.

The mitochondrial signature is interesting - intact mitochondrial function is protective. This could be related to:
1. Tumors with intact OXPHOS rely less on glycolysis (Warburg)
2. Or could be a marker of better-differentiated cells with more mitochondria
3. Or could reflect metabolic plasticity

Now let me draft the final response. I want to make sure I cover all required sections.

Format-wise, I'll use markdown headings and concise tables where appropriate. The user wants a substantive analysis but not bloated.</think>

# Prognostic Transcriptomic Interpretation – Colorectal Cancer (OS)

## 1. Overall biological interpretation

The prognostic signature separates into two coherent, biologically opposing programs:

- A **risk-associated (HR > 1) arm** dominated by genes linked to **epithelial–mesenchymal transition (EMT), TGF-β/FGF growth factor signaling, and immunosuppression via the adenosine axis**. The strongest single signal is *INHBB* (HR ≈ 1.43, FDR ≈ 1×10⁻³), a TGF-β superfamily ligand, together with the ZEB1-regulating lncRNA *ZEB1-AS1*, the cytoskeletal/EMT effectors *TPM4*, *ITGBL1*, *DCBLD2*, and *MAP1B*, the pro-survival kinase *AKT3*, and the adenosine-generating ectoenzyme *NT5E* (CD73). This pattern is the canonical transcriptomic footprint of an **invasive, dedifferentiated, immune-cold phenotype**.

- A **protective-associated (HR < 1) arm** enriched in **intestinal epithelial differentiation factors and core mitochondrial/oxidative-phosphorylation machinery**. *CDX2* and *CDX1* (master intestinal homeobox TFs), the intestinal lectin *LGALS4*, the brush-border motor *MYO5B*, and an unusually dense cluster of OXPHOS subunits (*NDUFA9*, *ATP5B*, *ATP5G1*, *OGDHL*, *CS*, *COA3*, *TIMM13*) and metabolic enzymes (*ACSS2*, *MCCC2*, *GLYCTK*, *PXMP2*) point to tumors that retain **differentiated enterocyte identity coupled to functional mitochondrial energy metabolism**.

Overall, the OS-associated transcriptomic landscape is consistent with a **"differentiated-epithelial / OXPHOS-intact" versus "EMT / TGF-β-driven / adenosine-suppressive" prognostic axis**, a framework repeatedly observed in CRC molecular subtyping (e.g., the CMS3/CMS4 contrast and CRIS subtypes).

---

## 2. Core biological programs

### Program A – EMT and invasive mesenchymal phenotype (Risk)
- **Direction:** Higher expression → worse OS.
- **Major supporting genes:** *ZEB1-AS1* (HR 1.37), *TPM4* (1.36), *ITGBL1* (1.30), *DCBLD2* (1.41), *MAP1B* (1.33), *SCEL* (1.25), *PTPN14* (1.36), *NIN* (1.35), *NAV3* (1.26).
- **Most appropriate pathway:** Hallmark *Epithelial Mesenchymal Transition*; Reactome R-HSA-5663202 ("Diseases of signal transduction by growth factor receptors") for the receptor/protease component.
- **Interpretation:** *ZEB1-AS1* cis-regulates *ZEB1*, a master EMT TF; *TPM4* and *MAP1B* remodel the actin/microtubule cytoskeleton required for migration; *ITGBL1* is a secreted integrin-like protein that potentiates TGF-β-driven EMT in CRC; *DCBLD2* and *NAV3* (neuron navigator) have been associated with cell-motility programs; *PTPN14* regulates Hippo/YAP and is a context-dependent tumor suppressor whose loss correlates with invasive phenotypes.
- **Strength:** Multiple, biologically convergent cytoskeletal/EMT effectors with consistent directional effect; externally well-documented EMT biology in CRC.
- **Limitations:** *PTPN14* is context-dependent (tumor suppressor in some, risk marker here) and the EMT program can also reflect stromal contamination (see §6).

### Program B – Intestinal epithelial differentiation (Protective)
- **Direction:** Higher expression → better OS.
- **Major supporting genes:** *CDX2* (HR 0.75), *CDX1* (0.78), *LGALS4* (0.77), *MYO5B* (0.75), *LGALS9* (0.75), *CCL15* (0.75).
- **Most appropriate pathway:** GO:0048565 ("intestinal epithelial cell differentiation"); Reactome R-HSA-1280215 ("Cytokine Signaling in Immune system" – for the chemokine *CCL15* that recruits immune cells to mucosal epithelium).
- **Interpretation:** *CDX1/CDX2* are the homeobox TFs that specify enterocyte identity; loss of *CDX2* is an established poor-prognosis feature in CRC. *LGALS4* (galectin-4) is a brush-border lectin restricted to mature intestinal epithelium. *MYO5B* drives apical trafficking in enterocytes. *LGALS9* (galectin-9) and *CCL15* support mucosal epithelial-immune cross-talk.
- **Strength:** Strong, internally coherent; *CDX2* is one of the most replicated prognostic biomarkers in CRC.
- **Limitations:** *CDX2* loss is partly stage/MSS-status dependent; the program may partly reflect MSI-H/differentiated biology rather than causation.

### Program C – Mitochondrial oxidative phosphorylation and central carbon metabolism (Protective)
- **Direction:** Higher expression → better OS.
- **Major supporting genes:** *NDUFA9* (HR 0.69, Complex I), *ATP5B* (0.75) and *ATP5G1* (0.75) (ATP synthase F1/F0), *OGDHL* (0.69, α-KG dehydrogenase-like), *CS* (0.75, citrate synthase), *COA3* (0.74, COX assembly), *TIMM13* (0.75, mitochondrial import), *ACSS2* (0.76), *MCCC2* (0.74), *GLYCTK* (0.71), *PXMP2* (0.72), *CRYM* (0.73).
- **Most appropriate pathway:** Reactome R-HSA-611105 ("Respiratory electron transport"); KEGG hsa00020 ("Citrate cycle / TCA cycle"); GO:0006119 ("oxidative phosphorylation").
- **Interpretation:** A coherent cluster spanning all five OXPHOS complexes and the TCA cycle, plus acetate and BCAA catabolism, indicates that tumors retaining mitochondrial bioenergetic capacity behave less aggressively. This is consistent with reports that OXPHOS-high CRC subtypes show better outcomes, whereas OXPHOS-low / glycolytic tumors are more stem-like and chemoresistant.
- **Strength:** Strong statistical effect sizes (HRs ≈ 0.69–0.75) with multiple independent subunits of the same machinery – unlikely to be a single gene's idiosyncrasy.
- **Limitations:** Mitochondrial transcripts can be confounded by stromal/immune cell content and overall tumor metabolic state; OXPHOS transcripts can also reflect cell-type-of-origin (normal colonocytes are highly oxidative).

### Program D – TGF-β superfamily and growth-factor receptor signaling (Risk)
- **Direction:** Higher expression → worse OS.
- **Major supporting genes:** *INHBB* (HR 1.43, the top risk gene), *FGF19* (1.29), *AKT3* (1.32), *PTPN14* (1.36), *NT5E* (1.31).
- **Most appropriate pathway:** Reactome R-HSA-170834 ("Signaling by TGF-beta family members"); KEGG hsa04010 ("MAPK signaling pathway"); KEGG hsa04151 ("PI3K-Akt signaling pathway").
- **Interpretation:** *INHBB* dimerizes to Activin B, which engages SMAD2/3 and has been implicated in CRC invasion and chemoresistance. *FGF19* drives proliferation through FGFR4 – a recognized oncogenic axis in colon cancer (the *FGF19–FGFR4–β-Klotho* complex). *AKT3* is a pro-survival kinase in the PI3K/AKT cascade. *NT5E* (CD73) generates extracellular adenosine, activating A2A receptors that suppress anti-tumor T cells and amplify pro-survival PI3K-AKT in tumor cells.
- **Strength:** Biologically tight convergence on a TGF-β / receptor-tyrosine-kinase / PI3K-AKT signaling axis with strong effect sizes.
- **Limitations:** *NT5E* may also reflect a stromal/immune cell-of-origin rather than tumor-cell autonomous signaling.

### Program E – Immune-modulatory / adenosine checkpoint signaling (mixed; predominantly Risk via NT5E)
- **Direction:** Mixed – *NT5E* (CD73) is risk; *LGALS9* and *CCL15* trend protective.
- **Major supporting genes:** *NT5E* (HR 1.31), *LGALS9* (0.75), *CCL15* (0.75), *BCL2L14* (0.76), *CASP6* (0.77).
- **Most appropriate pathway:** Reactome R-HSA-1643685 ("Signaling by Receptor Tyrosine Kinases" for the upstream adenosine/PKA arm); GO:0006955 ("immune response"); Hallmark *Apoptosis*.
- **Interpretation:** *NT5E*-derived adenosine is immunosuppressive; *LGALS9* can engage Tim-3 to either exhaust or activate T cells depending on context; *CCL15* is a chemokine that recruits monocytes/dendritic cells; *BCL2L14* and *CASP6* are pro-apoptotic effectors, suggesting residual apoptotic competence.
- **Strength:** Limited – only a small number of immune genes reach significance and direction is mixed.
- **Limitations:** Immune signatures are highly sensitive to tumor-infiltrating lymphocyte content and platform (see §6).

---

## 3. Key genes and interaction modules

| # | Gene | Direction / HR (FDR) | Role in core programs | Interaction type |
|---|------|---------------------|----------------------|------------------|
| 1 | **INHBB** | Risk / 1.43 (1×10⁻³) | Program D (TGF-β); links to Program A via Activin-induced EMT | Pathway co-membership (TGF-β/Activin–SMAD); ligand → receptor signaling (regulatory, not physical interaction with a single partner) |
| 2 | **CDX2** | Protective / 0.75 (3.6×10⁻²) | Program B (intestinal differentiation); antogonizes EMT | Transcription factor → *CDX1*, *LGALS4*, *MYO5B* regulatory axis (co-expression/co-regulation, not direct physical interaction) |
| 3 | **ZEB1-AS1** | Risk / 1.37 (8.6×10⁻³) | Program A (EMT) | lncRNA that cis-regulates *ZEB1* (regulatory); *ZEB1* in turn represses *CDX2* and epithelial cadherins – an indirect cross-program link |
| 4 | **NT5E (CD73)** | Risk / 1.31 (3.9×10⁻²) | Programs D & E | Cell-surface enzyme – direct physical interaction with extracellular AMP/adenosine substrates; partners with *ENTPD1* (CD39) at the biochemical level (co-expression / pathway co-membership) |
| 5 | **DCBLD2** | Risk / 1.41 (8.6×10⁻³) | Program A | Co-expressed with EMT and receptor-tyrosine-kinase programs; putative physical interaction with VEGFR/Nrp family reported (literature; **indirect**, not confirmed in this dataset) |
| 6 | **TPM4** | Risk / 1.36 (8.9×10⁻³) | Program A | Direct physical interaction with actin (Actb/Actg); co-expression with *MAP1B* reflects cytoskeletal remodeling (co-expression network) |
| 7 | **AKT3** | Risk / 1.32 (3.9×10⁻²) | Programs D & E | Direct physical interaction as kinase; downstream of both PI3K and adenosine-A2A signaling (pathway co-membership with *PTPN14*, *NT5E*) |
| 8 | **NDUFA9** | Protective / 0.69 (8.6×10⁻³) | Program C | Direct physical participation in Complex I; co-expression with *ATP5B*, *ATP5G1*, *OGDHL*, *CS* (pathway co-membership within OXPHOS) |
| 9 | **FGF19** | Risk / 1.29 (5.1×10⁻²) | Program D | Direct physical interaction with FGFR4/β-Klotho receptor complex (literature); signals through *AKT3* (pathway co-membership) |
| 10 | **ITGBL1** | Risk / 1.30 (3.1×10⁻²) | Program A | Secreted protein that physically engages integrins/TGF-β receptors (literature) and potentiates EMT; **indirect** link to *ZEB1* program |

> Note on interaction language: *co-expression* and *pathway co-membership* are reported as such; only genes with documented physical binding (e.g., *TPM4*–actin, *NT5E*–AMP, *FGF19*–FGFR4) are described as direct physical interactions. No dataset-internal evidence supports novel direct interactions.

---

## 4. Validation priorities

### Priority 1 – CDX2 / CDX1 differentiation axis as a prognostic biomarker
- **Category:** Biomarker.
- **Why prioritize:** *CDX2* is the single most replicated favorable prognostic marker in CRC; its co-protection with *CDX1*, *LGALS4*, *MYO5B* forms an internal "differentiation cluster" that should outperform any single gene.
- **Evidence in dataset:** Multiple protective intestinal-identity genes with consistent HRs 0.75–0.78, FDR 0.04–0.06.
- **External evidence:** Extensive CRC IHC and mRNA literature supports *CDX2* loss as adverse, but is partly confounded by MSI-H status and right-sided location.
- **Next step:** Build a 4-gene "intestinal differentiation score" (CDX2/CDX1/LGALS4/MYO5B) and validate in an independent CRC OS cohort with adjustment for stage, MSI, sidedness, and BRAF.
- **Status:** **Supported hypothesis** (well-established biology; current dataset confirms direction).

### Priority 2 – NT5E (CD73) / adenosine axis as a therapeutic target
- **Category:** Therapeutic target.
- **Why prioritize:** *NT5E* is druggable (small-molecule CD73 inhibitors such as oleclumab are in oncology trials). Its risk association in this dataset, together with *AKT3*, suggests actionable biology.
- **Evidence in dataset:** HR 1.31, FDR 0.04; converges with *AKT3* on the PI3K/AKT signaling module.
- **External evidence:** Strong preclinical CRC data; ongoing clinical development (anti-CD73 antibodies) in NSCLC and beyond, but CRC-specific efficacy still uncertain.
- **Next step:** Test *NT5E* mRNA/IHC against anti-CD73 response in CRC PDX/clinical cohorts; assess whether NT5E-high tumors show immune-cold features (CD8 IHC, IFNG signature).
- **Status:** **Supported hypothesis** (target plausibility is established; CRC-specific prognostic utility is supported but causal/treatment evidence remains exploratory).

### Priority 3 – ZEB1-AS1 / EMT module as a mechanistic and biomarker hypothesis
- **Category:** Mechanistic / Biomarker.
- **Why prioritize:** *ZEB1-AS1* plus *TPM4*, *ITGBL1*, *MAP1B*, *DCBLD2* form a tightly directional EMT signature that could stratify patients for adjuvant therapy or follow-up intensity.
- **Evidence in dataset:** Multiple risk genes across cytoskeletal and receptor arms (HRs 1.30–1.41).
- **External evidence:** *ZEB1-AS1* is reported to promote CRC proliferation and metastasis; *ITGBL1* is a recognized EMT amplifier in CRC.
- **Next step:** Build a small EMT lncRNA-cytoskeleton score and test it against disease-free survival and chemotherapy benefit in stage II/III CRC cohorts; orthogonalize against CMS subtype calls.
- **Status:** **Exploratory hypothesis** (biologically coherent but causal evidence in CRC OS is incomplete).

### Priority 4 – Mitochondrial OXPHOS gene set as a protective metabolic program
- **Category:** Mechanistic hypothesis / Biomarker.
- **Why prioritize:** The signature is unusually dense (8+ OXPHOS/TCA genes with HRs 0.69–0.75) and the effect sizes are among the largest in the protective arm. If validated, OXPHOS-high tumors may identify patients with favorable biology and possible sensitivity to OXPHOS-targeting agents.
- **Evidence in dataset:** *NDUFA9*, *OGDHL*, *ATP5G1*, *ATP5B*, *CS*, *COA3*, *TIMM13* all HR < 0.76.
- **External evidence:** Consistent with reports that OXPHOS-high / glycolysis-low CRC subtypes have better outcomes; but also with the contrary view that some OXPHOS-competent tumors are chemoresistant stem-like cells.
- **Next step:** Compute a ssGSEA OXPHOS score and test against OS and adjuvant chemotherapy interaction in TCGA-COAD/READ and an external cohort.
- **Status:** **Supported hypothesis** (signal is internally strong and externally plausible).

### Priority 5 – INHBB / Activin B signaling as a mechanistic driver
- **Category:** Mechanistic hypothesis.
- **Why prioritize:** *INHBB* is the top single-gene risk signal (HR 1.43, FDR 1×10⁻³), biologically tractable (TGF-β superfamily), and has ligands amenable to intervention (e.g., follistatin, neutralizing antibodies).
- **Evidence in dataset:** Top-ranking risk gene; pathway convergence with *FGF19* and *AKT3*.
- **External evidence:** Activin B is implicated in CRC invasion and ECM remodeling, but direct OS data are limited.
- **Next step:** Measure serum Activin B and tumor *INHBB* mRNA in a prospective CRC cohort; test Activin-neutralizing strategies in *INHBB*-high PDX models.
- **Status:** **Exploratory hypothesis** (single-gene dominance; needs replication and functional validation).

---

## 5. Evidence grounding (synthesis)

| Claim | Evidence type | Independence |
|-------|---------------|--------------|
| EMT program drives poor OS in CRC | (i) Direct: *ZEB1-AS1*, *TPM4*, *ITGBL1*, *MAP1B* in input. (ii) Pathway: Hallmark EMT, Reactome signal transduction. (iii) Disease-association: extensive CRC EMT literature. (iv) Expression/tissue: EMT genes are largely mesenchymal-lineage expressed. | Multiple independent sources converge. |
| Intestinal differentiation is protective | (i) Direct: *CDX2*, *CDX1*, *LGALS4*, *MYO5B* in input. (ii) GO: intestinal epithelial differentiation. (iii) Disease-association: *CDX2* IHC literature. (iv) Genetic/clinical: CDX2 loss reproducibly associates with worse OS in TCGA and meta-analyses. | Strongly independent; well-established. |
| Mitochondrial OXPHOS is protective | (i) Direct: 8+ OXPHOS genes in input. (ii) Pathway: Reactome respiratory electron transport, KEGG TCA cycle. (iii) Published literature: OXPHOS-high CRC subtypes have better outcomes, with some contradictory data. | Directionally consistent; partly overlapping because all OXPHOS genes derive from the same mitochondrial transcript pool – not fully independent replicates of each other. |
| TGF-β / growth factor / PI3K-AKT axis drives risk | (i) Direct: *INHBB*, *FGF19*, *AKT3*. (ii) Pathway: Reactome TGF-β, KEGG PI3K-Akt. (iii) Drug: FGFR4 and AKT inhibitors in development. (iv) Literature: FGF19/FGFR4 axis is oncogenic in colon. | Convergent; *NT5E*–adenosine link partly overlapping with PI3K-AKT. |
| NT5E / adenosine = immunosuppressive risk | (i) Direct: *NT5E*. (ii) Pathway: Reactome purinergic signaling. (iii) Drug: anti-CD73 mAbs (oleclumab) in trials. (iv) Literature: adenosine-mediated immune evasion. | Direct and drug evidence converge; CRC-specific OS evidence is partial. |

**Conflicts and uncertainty:**
- *PTPN14* is described as a tumor suppressor in many contexts (YAP regulator), yet here its higher expression is risk-associated. This may reflect tumor-stromal origin of the *PTPN14* signal or a context-specific function.
- The OXPHOS-protective direction conflicts with a subset of literature suggesting OXPHOS competence can mark chemoresistant stem-like cells. Resolution requires stage- and treatment-stratified analyses.
- The EMT program and the differentiation program are biologically anti-correlated and may partly capture the **same underlying tumor dedifferentiation axis**, meaning the two signatures should be evaluated together rather than as fully independent predictors.

Where evidence is purely co-expression or pathway co-membership (e.g., the OXPHOS cluster), this is flagged as such; it is **not** interpreted as evidence of direct physical interactions.

---

## 6. Limitations and alternative explanations

1. **Tumor purity and stromal/immune composition.** EMT genes (*TPM4*, *MAP1B*, *ZEB1-AS1*), immune-modulatory genes (*NT5E*, *LGALS9*, *CCL15*), and even OXPHOS transcripts can derive substantially from stromal, immune, or normal epithelial cells. Apparent "tumor-intrinsic" prognostic effects may partly reflect microenvironmental composition. **How to investigate:** Adjust for ESTIMATE/MCP-counter scores; replicate in stromal- and immune-deconvolved expression; perform IHC or spatial transcriptomics for representative markers (ZEB1, CD73, CDX2, TOMM20).

2. **Confounding by stage, MSI, sidedness, BRAF/RAS mutations.** Several protective genes (*CDX2*, *LGALS4*) and risk genes (*INHBB*, *NT5E*) correlate with MSI status or anatomical site. The reported HRs are unadjusted for these clinical covariates in the supplied table. **How to investigate:** Multivariable Cox models including stage, MSI, sidedness, RAS/BRAF; stratified analyses.

3. **Treatment exposure heterogeneity.** OS differences may reflect differential benefit from adjuvant chemotherapy rather than intrinsic tumor biology. OXPHOS-high tumors, for example, may simply be more chemosensitive. **How to investigate:** Test for treatment-by-gene interaction in stage II/III cohorts with documented adjuvant therapy.

4. **Probe-level and unannotated features.** A substantial fraction of the strongest signals (*PROBE_237290_at*, *PROBE_233690_at*, *PROBE_1566163_at*, *PROBE_233364_s_at*, *PROBE_241026_at*, *PROBE_239908_at*, *PROBE_232268_at*, *PROBE_1560986_a_at*, *PROBE_239672_at*, *PROBE_1563414_at*, *PROBE_1555968_a_at*, *PROBE_1566163_at*) are Affymetrix probe identifiers without resolved gene symbols. These should be re-mapped to current genome annotations before being included in any signature, since probe-to-gene assignment may have changed across array generations and may reflect mis-hybridizing probes.

5. **Statistical and platform considerations.** Even with FDR < 0.05, the number of significant genes is large (≈90 here), implying that the prioritized programs should be confirmed in an independent OS cohort of comparable size, ideally on RNA-seq rather than microarray, before any clinical biomarker use. Co-expression of multiple OXPHOS genes is partly a single "mitochondrial transcript" signal rather than independent biological evidence and should be summarized as one program.

---

## Bottom-line summary

The prognostic transcriptome of this CRC cohort is best explained by **two opposing biological axes**: (i) an **EMT / TGF-β-FGF / adenosine-suppressive axis** that drives shorter OS, and (ii) a **CDX2-driven intestinal differentiation coupled to intact mitochondrial OXPHOS** that protects OS. The most actionable findings are **CDX2/CDX1 as biomarkers**, **NT5E (CD73) as a therapeutic target hypothesis**, and the **OXPHOS and EMT gene sets** as combined prognostic and biologic classifiers. All of these are *supported hypotheses* in this dataset; INHBB-driven Activin signaling remains the leading mechanistic candidate for prospective functional validation.
